+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID06510374

Randomized Phase 3b Trial Comparing Nadofaragene Firadenovec Gene Therapy to Observation in Intermediate Risk Non-Muscle Invasive Bladder Cancer

Led by Ferring Pharmaceuticals · Updated on 2026-10-30

454

Participants Needed

116

Research Sites

208 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a phase 3b randomized, controlled trial to compare nadofaragene firadenovec versus observation in participants with intermediate risk non-muscle invasive bladder cancer IR NMIBC. The study aims to evaluate treatment effects on recurrence-free survival over a 24-month period. This trial is sponsored by Ferring Pharmaceuticals and focuses on participants who have undergone prior tumor resection and meet specific risk criteria according to established urological guidelines. Participants assigned to the nadofaragene firadenovec group will receive quarterly instillations of this vector-based gene therapy designed to boost the bodys interferon alfa-2b response for up to 24 months. Those in the observation group will be followed according to routine surveillance schedules recommended by the American Urological Association AUA and the Society of Urologic Oncology SUO, also on a quarterly basis for 24 months. Disease evaluations for treated participants will occur within two weeks prior to each treatment instillation. Throughout the study, participants will undergo regular disease evaluations and monitoring for adverse events up to 24 months. Researchers will measure recurrence-free survival at 12 and 24 months as primary and secondary outcomes. The trial design includes randomized allocation without masking, and participants will be followed during the treatment period and beyond for safety and efficacy assessments, with total participation lasting up to 24 months.

CONDITIONS

Brief Title

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

Research Team

F

Ferring Pharmaceuticals

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here